Cargando…

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab

SIMPLE SUMMARY: Molecular biology knowledge has enabled the incorporation of targeted therapies, such as the anti-angiogenic drug bevacizumab, into combined chemotherapy regimens for the treatment of metastatic colorectal cancer. However, to date, there are no reliable useful biomarkers to predict t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortiz-Morales, M. José, Toledano-Fonseca, Marta, Mena-Osuna, Rafael, Cano, M. Teresa, Gómez-España, Auxiliadora, la Haba-Rodríguez, Juan R. De, Rodríguez-Ariza, Antonio, Aranda, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265004/ https://www.ncbi.nlm.nih.gov/pubmed/35804826 http://dx.doi.org/10.3390/cancers14133054

Ejemplares similares

The Combination of Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer
por: Toledano-Fonseca, Marta, et al.
Publicado: (2021)

Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer
por: Toledano-Fonseca, Marta, et al.
Publicado: (2020)

Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
por: García-Ortiz, María Victoria, et al.
Publicado: (2023)

Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects
por: García-Ortiz, María Victoria, et al.
Publicado: (2023)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
por: Sánchez-Rovira, P., et al.
Publicado: (2013)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts
por: Guil-Luna, Silvia, et al.
Publicado: (2020)

SWATH‐based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours
por: López‐Sánchez, Laura M., et al.
Publicado: (2019)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
por: Krizova, Deli, et al.
Publicado: (2014)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
por: Díaz-Rubio, Eduardo, et al.
Publicado: (2012)

A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer
por: Peñarando, Jon, et al.
Publicado: (2018)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
por: Rusovici, Raluca, et al.
Publicado: (2011)

Does anti-VEGF bevacizumab improve survival in experimental sepsis?
por: Besnier, Emmanuel, et al.
Publicado: (2017)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance
por: Alidzanovic, Lejla, et al.
Publicado: (2016)

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
por: Vivancos, Ana, et al.
Publicado: (2019)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF
por: Sharma, Rajesh K., et al.
Publicado: (2010)

Morphological Changes of Cortical and Hippocampal Neurons after Treatment with VEGF and Bevacizumab
por: Latzer, Pauline, et al.
Publicado: (2016)

Blocking VEGF by Bevacizumab Compromises Electrophysiological and Morphological Properties of Hippocampal Neurons
por: Latzer, Pauline, et al.
Publicado: (2019)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes: Basal Plus Trial
por: Umpierrez, Guillermo E., et al.
Publicado: (2013)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
por: Salazar, Ramón, et al.
Publicado: (2020)

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
por: Starlinger, P, et al.
Publicado: (2012)

A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
por: Panoilia, Eirini, et al.
Publicado: (2015)

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A
por: Han, K, et al.
Publicado: (2016)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
por: Bota, Daniela A, et al.
Publicado: (2018)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

The Influence of Aging on the Functional Connectivity of the Human Basal Ganglia
por: Rodriguez-Sabate, Clara, et al.
Publicado: (2022)

Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye
por: Jiang, Xiaodan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gmqvc9e3tfdti60j8adgt91sk2